RaySearch Laboratories AB (publ) Interim Report January 1 – June 30, 2007

Read original

January 1 – June 30, 2007
• Net sales for the period amounted to SEK 33.5 M (28.6)
• Profit after tax was SEK 10.7 M (8.3)
• Earnings per share after tax amounted to SEK 0.94 (0.72)
• Operating profit amounted to SEK 14.3 M (11.3)
• Cash flow from operating activities amounted to SEK 19,8 M (19.2)
• New collaboration agreement with Varian Medical Systems was signed in May

After the end of the reporting period
• New collaboration agreement with TomoTherapy was signed in August
• Application to the FDA for 510(k) approval for the sale of the Compass product platform in the US was filed in August

CEO comments
“We are highly pleased to announce today a new collaboration agreement with TomoTherapy, which becomes our fifth partner,” says Johan Löf, President and CEO of RaySearch.

“We have also posted a favorable financial development during the period and we are involved in a number of discussions regarding new license agreements so I view the future with great optimism.”

Stockholm, August 29, 2007

RaySearch Laboratories AB
Johan Löf, President and CEO

About Us

RaySearch Laboratories AB (publ) has been pushing the limits of advanced cancer treatment since 2000. Using progressive algorithms, RaySearch develops world leading software used by thousands of the most cutting-edge cancer clinics in the world. The algorithms are based upon founder and CEO Johan Löf’s scientific knowledge, acquired during his PhD on radiation treatment of moving tumors at the Karolinska Institute. The treatment planning system RayStation and the OIS RayCare are the result of extensive development during years of research, and today used to improve chances of survival and quality of life for cancer patients. We fight for a world where cancer is conquered.


Documents & Links